These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Altering the mitochondrial genome: is it just a technical issue? Szebik I Camb Q Healthc Ethics; 1999; 8(3):369-74. PubMed ID: 10475695 [No Abstract] [Full Text] [Related]
7. Intravesical antisense therapy for cystitis using TAT-peptide nucleic acid conjugates. Tyagi P; Banerjee R; Basu S; Yoshimura N; Chancellor M; Huang L Mol Pharm; 2006; 3(4):398-406. PubMed ID: 16889433 [TBL] [Abstract][Full Text] [Related]
8. Current perspectives in the treatment of mitochondrial DNA diseases. Turnbull DM; Lightowlers RN; Taylor RW Funct Neurol; 2001; 16(4 Suppl):89-96. PubMed ID: 11996536 [No Abstract] [Full Text] [Related]
9. Outcome measures for children with mitochondrial disease: consensus recommendations for future studies from a Delphi-based international workshop. Koene S; van Bon L; Bertini E; Jimenez-Moreno C; van der Giessen L; de Groot I; McFarland R; Parikh S; Rahman S; Wood M; Zeman J; Janssen A; Smeitink J J Inherit Metab Dis; 2018 Nov; 41(6):1267-1273. PubMed ID: 30027425 [TBL] [Abstract][Full Text] [Related]
10. Long-term outcome and clinical spectrum of 73 pediatric patients with mitochondrial diseases. Debray FG; Lambert M; Chevalier I; Robitaille Y; Decarie JC; Shoubridge EA; Robinson BH; Mitchell GA Pediatrics; 2007 Apr; 119(4):722-33. PubMed ID: 17403843 [TBL] [Abstract][Full Text] [Related]